This website is partially compliant with The European Accessibility Act. The accessibility icon on this website provides accessibility support. We can provide an accessible version of any documents/links on request if required via [email protected] ••• Be Fraud Aware: By staying vigilant, you can help yourself from being the victim of fraud.

Back

Overview Wealth Planning Service Discretionary Investment Service Other Investment Services
Overview Investment Solutions Pension Solutions SDIO Application Forms – Intermediaries
Overview

Cantor Fitzgerald Asset Management

Overview Market Updates Useful Forms Sustainability Disclosures
Fund Centre

Multi-Asset Funds

Overview Multi-Asset 70 Fund Multi-Asset 50 Fund Multi-Asset 30 Fund Balanced Fund

Equity Funds

Overview Irish Equity Fund Global Equity Fund Global Equity UCITS Fund Global Equity Income Fund

ESG/Ethical Funds

Overview Green Effects Fund Paris Aligned Global Equity Fund Ethical Fund Ethical Global Equity Fund

Thematic Funds

Overview Technology Fund Infrastructure Impact Fund New Haven Housing Fund

Alternative Investment Fund

Alternative Investment Fund (RIAIF)

Fixed Income & Cash Funds

Overview Cash Fund Long Bond Fund Fixed Interest Fund
Overview

Corporate

Overview

Real Estate

Overview Capital Markets & Advisory

Credit Unions

Overview Investment Advisory Services
Debt Capital Markets Probate Services
Dedicated to institutional wealth, stakeholder value, and a sustainable future

Dedicated to institutional wealth, stakeholder value, and a sustainable future

Overview Investment Services Stewardship
Supportive of you, your custodial 
vision, and your philanthropic goals

Supportive of you, your custodial 
vision, and your philanthropic goals

Weekly Trader and Bond Markets 27.05.24 – Grafton Group, Microsoft & AstraZeneca

27.05.2024



Opportunities this week:

  • We believe it is an opportune time to highlight Grafton as a buying opportunity, with the upcoming general election in the UK a likely positive catalyst for the company. (BUY PT: £11.30)
  • We reiterate our BUY rating on Microsoft following the recent announcement of its new range of PCs which will be optimised for artificial intelligence tasks. (BUY PT: $479)
  • We reiterate our take profits call on AstraZeneca reflecting a stretched valuation in our view, we are also dropping the stock from our research coverage